[RabbitAngstrom]

A co-worker in my lab pointed out that Myriad's stock is actually rising[1] after the decision.The best guess is that Myriad's competitive advantage is shifting to the enormous amounts of BRCA sequences they have obtained -- this would increase the cancer-vs-normal mutation prediction power considerably.

[1] - http://www.google.com/finance?cid=658315

[jfb]

Also, they now have legal certainty whereas before the decision there was a chance the whole kit and kaboodle would have been tossed out.

[michaelhoffman]

Not anymore.